UNAIDS Reference Group on Estimates, Modelling, and Projections

29 July – 1 August

Monday:

Time	Duration (mins)	Topic	Presenter(s)/ Lead Discussant
9.00	20	Welcome and introductions	Mary Mahy
9.20	30	Overview of 2024 estimates	Eline Korenromp
9.50	10	Meeting objectives	Cari van Schalkwyk
Session 1: Advanced HIV disease **Objective:** • Validate Spectrum estimates of AHD (defined as CD4 < 200) • Identify needs for future AHD estimates from modelled results and surveillance data sources			
10.00	15	• Overview of WHO AHD work area and country implementation plans of CD4 testing • Summary of WHO systematic review of AHD	Nathan Ford
10.15	10	Advanced HIV Disease estimates from PHIA surveys	Shona Dalal
10.25	20	Comparing Spectrum estimated AHD prevalence among PLHIV to: • PHIA-reported AHD prevalence among PLHIV • Country program GAM-reported AHD at diagnoses or ART (re-)initiation • WHO systematic review of AHD prevalence • AHD at ART initiation (IeDEA)	Oliver Stevens
10.45	15	TEA	
11.00	60	Discussion	
12.00	90	LUNCH	
Session 2: Causes of Death among PLHIV **Objectives:** • Review implementation of CM and TB death estimates in Spectrum, within the envelope of Spectrum-estimated HIV-related deaths			
13.30	90	Tuberculosis	WHO
15.00	10	TEA	
15.10	90	Cryptococcal Meningitis	Radha Rajasingham
Session 3: Mortality among PLHIV on ART **Objectives:** • Validate Spectrum estimates of on-ART mortality against various sources • Present new approach to Spectrum mortality structure given incomplete CD4 data in most IeDEA cohorts			
16.40	50	Mortality trends among PLHIV in AHRI population cohort, KwaZulu Natal	Mark Siedner
17.30		CLOSE	

Tuesday:

Time	Duration (mins)	Topic	Presenter(s)/ Lead Discussant
Session 3: Mortality among PLHIV on ART - continued			
9.00	30	Mortality among people on ART from routine monitoring data through PEPFAR quarterly MER reporting	Sara Herbst
9.30	60	New approach to Spectrum mortality structure with reduced CD4 data availability	
10.30	10	TEA	
Session 4: Excess mortality among PLHIV **Objective:** • Review method to separate AIDS vs non-AIDS deaths			
10.40	30	Excess mortality AIDS vs non-AIDS: • Proposed approach for additive mortality • Proposed method for regions other than WCENA • Impact on estimates by region	Rob Glaubius/Jeff Imai-Eaton
11.10	20	Impact of proposed excess mortality split-off on CSAVR estimates	Guy Mahiane
11.30	60	Discussion	
12.30	90	LUNCH	
Session 5: Treatment Interruption **Objectives:** • Review outcomes from 2024 estimates • Provide recommendations on guidance and definitions for calculating Spectrum interruption inputs			
14.00	15	Impact of new default rates, how many countries adopted defaults vs. entered national program data, etc	Eline Korenromp / Rob Glaubius
14.15	15	WHO definitions of loss to follow-up and treatment interruption	Hiwot Haile-Selassie
14.30	15	GAM-reported cohort retention on ART, data by country and over time	Eline Korenromp/ John Stover / Anna Yakusik
14.45	15	Proposal: Default relationship between WHO treatment interruption and treatment discontinuation	Jeff Imai-Eaton/ Rob Glaubius
15.00	60	Discussion	
16.00	10	TEA	
Session 6: World Population Prospects 2024 update **Objective:** • **Review impact of new population estimates on HIV estimates**			
16.10	20	Impact of WPP 2024 vs 2022 estimates on HIV estimates	Rob Glaubius
16.30	30	Discussion	
17.00		CLOSE	

Wednesday:

Time	Duration (mins)	Topic	Presenter(s)/ Lead Discussant
Session 7: Dynamical modelling of HIV trends in KPs in sub-Saharan Africa **Objective:** • Review updates to Goals-ARM			
9.00	20	Key population modelling technical working group: aims, processes, and deliverables	Sharmistha Mishra
9.20	20	Goals-ARM development update	Rob Glaubius
9.40	65	Discussion	
10.45	15	TEA	
Session 8: New infections by Key Population and their partners **Objective:** • Review methods of estimating uncertainty in estimates			
11.00	5	Introduction	Keith Sabin
11.05	10	Key population size estimates used in Goals	Keith Sabin
11.15	15	Methods, including uncertainty intervals, hierarchies of models & sources for population size estimates and infections	Eline Korenromp
11.30	15	Goals calibrations, including country inputs and feedback & data and model triangulations	John Stover
11.45	15	Results, interpretation and next steps	Rachel Esra / Eline Korenromp
12.00	45	Discussion	
13.00	60	LUNCH	
Session 9: Sub-national HIV estimates **Objective:** • Review the SHIPP tool methods and make recommendations about its suitability and/or future development			
14.00	75	Sub-national HIV estimates In Priority Populations (SHIPP) workbook tool	Katie Risher
15.15	30	Naomi issues	Rachel Esra
15.45	15	TEA	
Session 10: Sub-national EPP stratification **Objective:** • Review likelihood structure and make recommendations about removing sub-national EPP stratification			
16.00	60	Replacing sub-national EPP stratification: Proposed likelihood structure for weighting ANC data	Jeff Imai-Eaton
17.00		CLOSE	

Thursday

Time	Duration (mins)	Topic	Presenter(s)/ Lead Discussant
Session 11: ART coverage data discrepancies **Objectives:** • **Plan further work related to ART coverage data discrepancies** • **Develop guidance and examples for countries to apply** • **Review current uncertainty on ART numbers and proposed adjustments**			
9.00	30	ART adjustments in the 2024 HIV estimates: • Summary of country adjustments • Rationale/ evidence supporting adjustment • Summary of ongoing DQA activities	Rachel Esra / Ian Wanyeki
9.30	10	Estimating subnational unmet need for ART for using discounted ART data	Rachel Esra
9.40	20	ANC ART coverage analysis and impact	Jeff Imai-Eaton
10.00	20	Methods to interrogate and adjust ART programme data in Malawi	Andreas Jahn / Stone Mbiriyawanda
10.20	20	ART dashboard and validation process in Kenya	Morris Ogero
10.40	40	Discussion	
11.20	10	TEA	
11.30	20	Proposed refined method to estimate uncertainty on Spectrum country-level ART numbers	John Stover
11.50	40	Discussion	
12.30		LUNCH	
Session 12: Age distribution of new infections **Objectives:** • **Review update to generalized epidemic default age incidence rate ratio pattern** • **Review evidence on incidence age pattern shifting to older ages** • **Consider default pattern and model specification for time-varying age incidence rate ratios**			
14.00	15	• Summary of recommendations from 'HIV incidence in Sub-Saharan Africa' Reference Group meeting • Empirical evidence on time-varying incidence rate ratios	Oli Stevens
14.15	25	• Default age incidence rate ratios: Update the generalized epidemic pattern considering recent incidence and serology surveys • Simultaneous fitting to survey prevalence, survey ART coverage, and programme ART by age	Rob Glaubius
14.40	20	Model for time-varying incidence rate ratios and default pattern	Jeff Imai-Eaton/ Rob Glaubius
15.00	60	Discussion	
16.00		CLOSING REMARKS	